Late-Stage or Nothing: How Big Pharma Is Rewriting the M&A Playbook One NDA Away From Filing
Teva's $900M Emalex deal for NDA-ready ecopipam in Tourette syndrome signals a pharma M&A shift: buy at Phase 3...
Biotech Acquisitions
Teva's $900M Emalex deal for NDA-ready ecopipam in Tourette syndrome signals a pharma M&A shift: buy at Phase 3...